The I/O 2.0-combo tech race is on: Merck bags oncolytics player Viralytics in $394M buyout
Last spring the small Australian biotech Viralytics made a big splash at the annual AACR meeting, turning up in the showcase spot with an intriguing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.